{"id":9549,"date":"2026-11-13T14:32:57","date_gmt":"2026-11-13T13:32:57","guid":{"rendered":"https:\/\/www.pjpharma.it\/?p=9549"},"modified":"2026-11-13T15:33:29","modified_gmt":"2026-11-13T14:33:29","slug":"rinofast-clinical-study-nasal-congestion","status":"publish","type":"post","link":"https:\/\/www.pjpharma.it\/en\/rinofast-clinical-study-nasal-congestion\/","title":{"rendered":"Rinofast Clinical Study on Nasal Congestion"},"content":{"rendered":"\n

Rinofast clinical study at a glance<\/h2>\n\n\n\n

In a prospective observational study of Rinofast<\/strong> conducted by Gruppo FarmaImpresa in February 2025, the total SNOT-22 score<\/strong> was lower at the end of treatment than at baseline (p < 0.001<\/strong>). The study assessed nasal symptoms and their impact on quality of life.<\/p>\n\n\n\n

Nasal congestion can occur with allergic rhinitis, rhinosinusitis, the common cold or exposure to environmental irritants. Related symptoms include nasal discharge and facial pressure. Persistent obstruction can also affect sleep and daily activities. The EPOS 2020 guidelines<\/a> and ARIA recommendations<\/a> provide clinical context for rhinosinusitis and allergic rhinitis, respectively.<\/p>\n\n\n\n

Rinofast Spray<\/strong><\/a> is a nasal spray medical device developed for nasal hygiene and to help relieve congestion.<\/p>\n\n\n\n

Study design and SNOT-22 assessment<\/h3>\n\n\n\n

Gruppo FarmaImpresa enrolled patients with nasal congestion and symptoms consistent with rhinitis or rhinosinusitis in a prospective observational study.<\/p>\n\n\n\n

The Sino-Nasal Outcome Test (SNOT-22)<\/strong> is a 22-item questionnaire that measures the severity of sinonasal symptoms and their impact on quality of life.<\/p>\n\n\n\n

The questionnaire covers symptoms and their effects, including:<\/p>\n\n\n\n

    \n
  • nasal obstruction<\/li>\n\n\n\n
  • runny nose<\/li>\n\n\n\n
  • sneezing<\/li>\n\n\n\n
  • facial pressure and pain<\/li>\n\n\n\n
  • changes in sense of smell<\/li>\n\n\n\n
  • sleep disturbances<\/li>\n\n\n\n
  • effects on mood and daily functioning<\/li>\n<\/ul>\n\n\n\n

    Higher scores indicate a greater symptom burden.<\/p>\n\n\n\n

    Patients were assessed at baseline (T0) and at the end of treatment (T1).<\/p>\n\n\n\n

    Clinical results for nasal congestion<\/h3>\n\n\n\n

    The total SNOT-22 score decreased from baseline to the end of treatment (p < 0.001<\/strong>).<\/p>\n\n\n\n

    The study reported:<\/p>\n\n\n\n

      \n
    • Less nasal obstruction<\/li>\n\n\n\n
    • Easier nasal breathing<\/li>\n\n\n\n
    • Less nasal discharge<\/li>\n\n\n\n
    • Better sleep<\/li>\n\n\n\n
    • Less emotional impact from symptoms<\/li>\n<\/ul>\n\n\n\n

      Rinofast nasal spray and its intended use<\/h3>\n\n\n\n

      Rinofast Spray contains 2.5% hypertonic saline and methylsulfonylmethane (MSM). It is designed to support nasal hygiene and help relieve congestion and related symptoms.<\/p>\n\n\n\n

      When is Rinofast used?<\/h3>\n\n\n\n

      Rinofast is intended to help manage nasal congestion and related symptoms, including:<\/p>\n\n\n\n

        \n
      • Nasal congestion<\/li>\n\n\n\n
      • Symptoms associated with allergic or non-allergic rhinitis<\/li>\n\n\n\n
      • Symptoms associated with rhinosinusitis<\/li>\n\n\n\n
      • Congestion associated with the common cold<\/li>\n\n\n\n
      • Nasal obstruction that affects sleep<\/li>\n<\/ul>\n\n\n\n

        Rinofast for international distribution and private label<\/h3>\n\n\n\n

        Gruppo FarmaImpresa manufactures medical devices, food supplements and cosmetics. Rinofast is available to companies and distributors as a ready-to-market product<\/strong> or for private-label projects<\/strong>, with clinical and regulatory support.<\/p>\n\n\n